Patents by Inventor Sarah Low

Sarah Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 11884744
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: January 30, 2024
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • ANTI-NRP1A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20230416378
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Application
    Filed: April 7, 2023
    Publication date: December 28, 2023
    Inventors: Nina ZIPPEL, Pankaj GUPTA, Fei HAN, Yining HUANG, Sarah LOW, Juergen PRESTLE, Leo THOMAS
  • Anti-NRP1A antibodies and their uses for treating eye or ocular diseases
    Patent number: 11661458
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Nina Zippel, Pankaj Gupta, Fei Han, Sarah Low, Juergen Prestle, Leo Thomas
  • BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119535
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119536
    Abstract: The invention relates to agonistic TrkB binding molecules, methods for improving agonistic TrkB binders, their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF
    Publication number: 20210107998
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 15, 2021
    Inventors: Sanjaya SINGH, Qi PAN, Rachel Rebecca BARRETT, Leslie S. JOHNSON, Pankaj GUPTA, Sarah LOW, Haixia WU
  • ANTI-NRP1A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20210087282
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Inventors: Nina ZIPPEL, Pankaj GUPTA, Fei HAN, Yining HUANG, Sarah LOW, Juergen PRESTLE, Leo THOMAS
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 10844138
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 24, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Anti-TrkB antibodies
    Patent number: 10793634
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
  • COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF
    Publication number: 20190241678
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: February 18, 2019
    Publication date: August 8, 2019
    Inventors: Sanjaya SINGH, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 10280231
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 7, 2019
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • ANTI-TRKB ANTIBODIES
    Publication number: 20180355046
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 7, 2018
    Publication date: December 13, 2018
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
  • COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF
    Publication number: 20170022294
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 26, 2017
    Applicants: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: SANJAYA SINGH, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu